Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre.

Eltawil KM, Berry R, Abdolell M, Molinari M.

HPB (Oxford). 2012 Mar;14(3):162-70. doi: 10.1111/j.1477-2574.2011.00420.x.

2.

Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study.

Eltawil KM, Berry R, Abdolell M, Molinari M.

HPB (Oxford). 2012 May;14(5):341-50. doi: 10.1111/j.1477-2574.2012.00455.x.

3.

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, Lee DY, Han KH, Chon CY, Park JY.

BMC Cancer. 2013 Jan 3;13:5. doi: 10.1186/1471-2407-13-5.

4.

Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.

Zhang DZ, Wei XD, Wang XP.

World J Gastroenterol. 2015 Apr 21;21(15):4635-43. doi: 10.3748/wjg.v21.i15.4635.

5.

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.

Jiang JH, Guo Z, Lu HF, Wang XB, Yang HJ, Yang FQ, Bao SY, Zhong JH, Li LQ, Yang RR, Xiang BD.

World J Gastroenterol. 2015 Apr 21;21(15):4627-34. doi: 10.3748/wjg.v21.i15.4627.

6.

Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.

Wang Y, Chen Y, Ge N, Zhang L, Xie X, Zhang J, Chen R, Wang Y, Zhang B, Xia J, Gan Y, Ren Z, Ye S.

Ann Surg Oncol. 2012 Oct;19(11):3540-6. doi: 10.1245/s10434-012-2368-5.

PMID:
22532305
7.

Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.

Song MJ, Bae SH, Lee JS, Lee SW, Song do S, You CR, Choi JY, Yoon SK.

Korean J Intern Med. 2016 Mar;31(2):242-52. doi: 10.3904/kjim.2015.112.

8.

Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma.

Zhu SL, Zhong JH, Ke Y, Ma L, You XM, Li LQ.

World J Gastroenterol. 2015 Aug 28;21(32):9630-7. doi: 10.3748/wjg.v21.i32.9630.

9.

Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre.

Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, Benjamin MS, Sherman M, Gallinger S, Burnett B, Feld R, Chen E, Greig PD, Grant DR, Knox JJ.

Clin Oncol (R Coll Radiol). 2006 Nov;18(9):684-92.

PMID:
17100154
10.

Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.

Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, Xu LF.

World J Gastroenterol. 2014 Dec 14;20(46):17483-90. doi: 10.3748/wjg.v20.i46.17483.

11.

Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma.

Cohen MJ, Bloom AI, Barak O, Klimov A, Nesher T, Shouval D, Levi I, Shibolet O.

World J Gastroenterol. 2013 Apr 28;19(16):2521-8. doi: 10.3748/wjg.v19.i16.2521.

12.

An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.

Pinato DJ, Sharma R.

Transl Res. 2012 Aug;160(2):146-52. doi: 10.1016/j.trsl.2012.01.011.

PMID:
22677364
13.

Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma.

Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH.

World J Gastroenterol. 2014 Jan 21;20(3):745-54. doi: 10.3748/wjg.v20.i3.745.

14.

Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.

Agarwal A, Yadav AK, Kumar A, Gupta S, Panwala HK, Redhu N, Hariprasad S, Ranjan P, Arora A, Gupta A.

Indian J Gastroenterol. 2015 Mar;34(2):117-26. doi: 10.1007/s12664-015-0544-9.

PMID:
25937484
15.

Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.

Li HL, Ji WB, Zhao R, Duan WD, Chen YW, Wang XQ, Yu Q, Luo Y, Dong JH.

World J Gastroenterol. 2015 Mar 28;21(12):3599-606. doi: 10.3748/wjg.v21.i12.3599.

17.

Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus.

Ye JZ, Zhang YQ, Ye HH, Bai T, Ma L, Xiang BD, Li LQ.

World J Gastroenterol. 2014 Dec 7;20(45):17141-7. doi: 10.3748/wjg.v20.i45.17141.

18.

Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.

Hsu KF, Chu CH, Chan DC, Yu JC, Shih ML, Hsieh HF, Hsieh TY, Yu CY, Hsieh CB.

Eur J Radiol. 2012 Mar;81(3):466-71. doi: 10.1016/j.ejrad.2010.12.058.

PMID:
21376495
19.

Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.

Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY.

J Vasc Interv Radiol. 2011 Jul;22(7):917-23. doi: 10.1016/j.jvir.2011.03.005.

PMID:
21571545
20.

Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival.

Biolato M, Miele L, Vero V, Racco S, Di Stasi C, Iezzi R, Zanché A, Pompili M, Rapaccini GL, La Torre G, Gasbarrini A, Grieco A.

World J Gastroenterol. 2014 Jul 7;20(25):8158-65. doi: 10.3748/wjg.v20.i25.8158.

Supplemental Content

Support Center